Startups 

In modern oncology, the ability to predict patient responses to cancer treatment is crucial for improving outcomes and minimizing adverse effects. VitroScan offers a cutting-edge platform that enables clinicians to individualize treatment strategies by providing highly accurate, reproducible data. This predictive capability enhances therapeutic efficacy and accelerates drug development by identifying optimal therapies early, reducing risk, and supporting the successful translation of innovative treatments from the lab to the clinic.

 At the core of VitroScan’s approach is its ex vivo micro-tumor platform, which closely replicates the tumor microenvironment (TME). By preserving the native architecture, cellular heterogeneity, and stromal interactions of patient-derived tissues, this platform enables accurate drug efficacy evaluations. Micro-tumors are maintained in a 3D matrix that mimics physiological conditions, allowing for the simultaneous assessment of drug responses, resistance mechanisms, and potential combination therapies under conditions that closely resemble in situ disease.

 In addition, VitroScan’s platform integrates precision patient testing with drug development, providing actionable insights that inform rational therapy selection and enhance clinical trial design. This approach reduces the risk of late-stage drug failure and accelerates the development of clinically relevant therapies. It also helps to inform patient stratification, ensuring that therapies are matched to the right patient populations in clinical trials.

 By bridging the gap between preclinical research and clinical application, VitroScan is revolutionizing cancer treatment. Its ability to simulate patient-specific treatment responses is crucial for advancing personalized oncology and improving the success of novel therapies in the fight against cancer. Through predictive testing, VitroScan is paving the way for more effective, targeted cancer treatments.